文献速递肿瘤 PET/CT核素与放射性配体治疗

18F-FDG与68Ga-PSMA PET/CT在乳头状肾细胞癌复发再分期中优于单独CT

18F-FDG and 68GA-Prostate-Specific Membrane Antigen PET/CT Perform Better Than CT Alone in Restaging Papillary Renal Cell Carcinoma Recurrence.
PubMed 文献 · Clin Nucl Med · 2021-01-01

本文报道一例77岁男性乳头状肾细胞癌患者,CT漏诊肺转移,经[18F]FDG PET/CT再分期发现,后接受舒尼替尼靶向治疗;随访中[68Ga]PSMA PET/CT在已知病灶外另发现CT漏诊的骨髓转移,提示两种分子影像在RCC再分期和疗效评估中优于传统影像。

要点

  • 18F-FDG PET/CT可发现CT漏诊的乳头状RCC肺转移。
  • 68Ga-PSMA PET/CT随访可发现CT漏诊的骨髓转移。
  • 分子影像有助于RCC再分期及靶向治疗反应评估。

核心结论

  • 18F-FDG与68Ga-PSMA PET/CT分子影像在RCC再分期和疗效评估中优于传统影像。

研究设计与样本

  • 单个病例报告,描述一例77岁男性乳头状RCC患者的再分期与随访影像。

主要发现

  • CT扫描漏诊了该患者的乳头状RCC肺转移,而18F-FDG PET/CT再分期成功发现。
  • 患者接受舒尼替尼靶向治疗。
  • 随访中68Ga-PSMA PET/CT在已知病灶之外发现了CT漏诊的骨髓转移。

临床怎么用

  • 对乳头状RCC复发再分期,可考虑18F-FDG或68Ga-PSMA PET/CT以发现CT漏诊病灶。
  • 随访中可用68Ga-PSMA PET/CT辅助评估靶向治疗反应及发现额外转移。

局限性

  • 证据仅来自单个病例报告,结论外推需谨慎。
  • 缺乏与CT的系统性对比数据及定量指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Renal cell carcinoma (RCC) shows variable FDG uptake; recently, PET/CT with prostate-specific membrane antigen (PSMA)-target radiotracers was demonstrated to be a promising tool in staging and restaging of RCC patients. We describe the case of a 77-year-old man with a lung metastasis of papillary RCC missed by CT scan who successfully underwent [18F]FDG PET/CT restaging. Targeted therapy with sunitinib was administered. A [68Ga]PSMA PET/CT performed during follow-up demonstrated, among the already known lesions, also a bone marrow metastasis, missed by previous CT scans. This case demonstrates that PET/CT molecular imaging with [18F]FDG and [68Ga]PSMA is superior to conventional imaging in RCC restaging and in assessing therapy response.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Gasparro D, Scarlattei M, Manuguerra R, et al. 18F-FDG and 68GA-Prostate-Specific Membrane Antigen PET/CT Perform Better Than CT Alone in Restaging Papillary Renal Cell Carcinoma Recurrence. Clin Nucl Med. 2021. PMID: 34374683. doi:10.1097/RLU.0000000000003660

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。